BridgeMD
A randomized controlled trial comparing sequential of two shots of CFA vs CFA + rFSH for Elective Fertility Preservation. The 2-shot protocol.
EU CTIS ID: 2023-506162-31-00
What this study is testing
To compare the number of mature oocytes (MII) retrieved after 2-shot sequential administration of Corifollitropin alpha (CFA) and a unique administration of CFA followed by the administration of rFSH daily for ovarian stimulation (OS) in patients undergoing elective fertility preservation in a progestin-primed ovarian stimulation (PPOS) protocol and GnRH-agonist (GnRH-a) triggering.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- AFC ≤ 20
- Anti-Mullerian hormone (AMH) ≤ 3ng/ml (AMH result of up to one year will be valid)
- Between 18 and 40 years old
- BMI > 18 and < 30 kg/m2
- Able to come to the Center to comply with the procedures of the study: blood tests, appointments and drug dispensation
You likely can't join if
- Medically indicated fertility preservation
- AFC > 20
- Polycystic ovarian syndrome (PCOS) according to the Rotterdam criteria
- FSH ≥ 20
- History of untreated autoimmune, endocrine, or metabolic disorders
- Contraindication for hormonal treatment
See the full eligibility criteria
- AFC ≤ 20
- Anti-Mullerian hormone (AMH) ≤ 3ng/ml (AMH result of up to one year will be valid)
- Between 18 and 40 years old
- BMI > 18 and < 30 kg/m2
- Able to come to the Center to comply with the procedures of the study: blood tests, appointments and drug dispensation
- Medically indicated fertility preservation
- AFC > 20
- Polycystic ovarian syndrome (PCOS) according to the Rotterdam criteria
- FSH ≥ 20
- History of untreated autoimmune, endocrine, or metabolic disorders
- Contraindication for hormonal treatment
- Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.